Results from a recent clinical trial suggest that the substantial increase in incidence of prostate cancer is unlikely to be due to increased exposure to environmental agents such as tobacco smoke, ionizing radiation, and/or occupational carcinogens. Rather, our results point toward an association between increased consumption of red meat and increased risk of prostate cancer and support the hypothesis that obesity in women and lack of physical activity are risk factors for developing prostate cancer.
Results from a recent paper suggest that the familial aggregation of prostate cancer does not appear to be due to an altered predisposition to prostate cancer in males who have a first degree relative with prostate cancer.
Prostate cancer is inherently more dangerous than many other cancers due to its tendency to spread before it can be detected. The use of aggressive diagnostic measures, including repeat transrectal ultrasound examinations and prostate biopsy, can reduce this inherent danger by detecting and treating prostate cancer early on so that it does not become life-threatening.
The data suggest that there are more than 4 million men at increased risk of developing PCa. Results from a recent paper provides information needed to develop and implement programs to identify high-risk men who should be offered prostate-specific antigen screening.
Telemedicine can be an effective tool in following up patients who have had biopsy and are receiving active treatment. Telemedicine can also be used to help manage other follow-up visits.
Telemedicine can be an effective tool for providing biologic information and therapies, and follow-up visits can be accomplished within an outpatient setting. Further studies are needed to determine whether telemedicine can improve patient satisfaction and outcomes of care.
A high proportion of patients offered to participate in clinical trials for prostate cancer were not enrolled, especially among younger, less educated, and non-treatment seeking men. Findings from a recent study suggest that recruiting men into clinical trials might be improved by offering trial information by means of the Internet, print, or both.
To diagnose [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), a definitive diagnosis of histological grade must be made (for example, Gleason score 7 or higher) and a biopsy must be done to confirm this diagnosis. If a biopsy cannot be done, the patient should have a second opinion before any treatment is started. A great deal of uncertainty still exists about what constitutes optimal treatment for prostate cancer. Although prostate cancer is treated by surgery, radiation therapy, hormonal therapy, chemotherapy and targeted therapies, none of these approaches are curative. Therefore, the management of prostate cancer remains challenging. The primary goal of prostate cancer treatment is to control symptoms and prolong life. The most effective way to do this is to reduce the volume of the prostate.
As we age, the probability of developing prostate cancer at any time point decreases exponentially. Age at diagnosis influences prognosis where early prostate cancers have an excellent outcome while late stage disease results in poor outcomes. On average only 1200 men developed prostate cancer between 1981 and 1990. Older men should be encouraged to participate in prostate cancer screening programs.
Recent findings revealed no difference in efficiency between regular follow-up visits at clinic visits and telemedicine sessions for prostate cancer detection. The study was limited by its small size.
The hormone ablation therapy was reported to be effective at reducing the progression of prostate cancer in trials but the effectiveness of ablation therapy for women with advanced prostate cancer remains unproven. The use of antiandrogens has been shown to be effective in treating former untreated men who present with HRPC. In addition, some studies suggest that adjuvant radiotherapy may decrease prostate cancer mortality. However, the efficacy of radiation therapy in all stages of prostate cancer still remains unknown. More research is needed to determine treatment modalities that maximize outcomes in HRPC.